BACKGROUND: The New York Heart Association (NYHA) functional class is a subjective estimate of a patient's functional ability based on symptoms that do not always correlate with the objective estimate of functional capacity, peak oxygen consumption (peak V(O2)). In addition, relationships between these 2 measurements have not been examined in the current medical era when patients are using beta-blockers, aldosterone antagonists, and cardiac resynchronization therapy (CRT). Using baseline data from the HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing) study, we examined this relationship. METHODS:One thousand seven hundred fifty-eight patients underwent a symptom-limited metabolic stress test and stopped exercise due to dyspnea or fatigue. The relationship between NYHA functional class and peak V(O2) was examined. In addition, the effects of beta-blockers, aldosterone antagonists, and CRT therapy on these relationships were compared. RESULTS: The NYHA II patients have a significantly higher peak Vo(2) (16.1 +/- 4.6 vs 13.0 +/- 4.2 mL/kg per minute), a lower ventilation (Ve)/V(CO2) slope (32.8 +/- 7.7 vs 36.8 +/- 10.4), and a longer duration of exercise (11.0 +/- 3.9 vs 8.0 +/- 3.4 minutes) than NYHA III/IV patients. Within each functional class, there was no difference in any of the exercise parameters between patients on or off of beta-blockers, aldosterone antagonists, or CRT therapy. Finally, with increasing age, a significant difference in peak Vo(2), Ve/V(CO2) slope, and exercise time was found. CONCLUSION: For patients being treated with current medical therapy, there still is a difference in true functional capacity between NYHA functional class II and III/IV patients. However, within each NYHA functional class, the presence or absence or contemporary heart failure therapies does not alter exercise parameters.
RCT Entities:
BACKGROUND: The New York Heart Association (NYHA) functional class is a subjective estimate of a patient's functional ability based on symptoms that do not always correlate with the objective estimate of functional capacity, peak oxygen consumption (peak V(O2)). In addition, relationships between these 2 measurements have not been examined in the current medical era when patients are using beta-blockers, aldosterone antagonists, and cardiac resynchronization therapy (CRT). Using baseline data from the HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing) study, we examined this relationship. METHODS: One thousand seven hundred fifty-eight patients underwent a symptom-limited metabolic stress test and stopped exercise due to dyspnea or fatigue. The relationship between NYHA functional class and peak V(O2) was examined. In addition, the effects of beta-blockers, aldosterone antagonists, and CRT therapy on these relationships were compared. RESULTS: The NYHA II patients have a significantly higher peak Vo(2) (16.1 +/- 4.6 vs 13.0 +/- 4.2 mL/kg per minute), a lower ventilation (Ve)/V(CO2) slope (32.8 +/- 7.7 vs 36.8 +/- 10.4), and a longer duration of exercise (11.0 +/- 3.9 vs 8.0 +/- 3.4 minutes) than NYHA III/IV patients. Within each functional class, there was no difference in any of the exercise parameters between patients on or off of beta-blockers, aldosterone antagonists, or CRT therapy. Finally, with increasing age, a significant difference in peak Vo(2), Ve/V(CO2) slope, and exercise time was found. CONCLUSION: For patients being treated with current medical therapy, there still is a difference in true functional capacity between NYHA functional class II and III/IV patients. However, within each NYHA functional class, the presence or absence or contemporary heart failure therapies does not alter exercise parameters.
Authors: Mandeep R Mehra; Jon Kobashigawa; Randall Starling; Stuart Russell; Patricia A Uber; Jayan Parameshwar; Paul Mohacsi; Sharon Augustine; Keith Aaronson; Mark Barr Journal: J Heart Lung Transplant Date: 2006-09 Impact factor: 10.247
Authors: Jonathan Myers; Ross Arena; Frederick Dewey; Daniel Bensimhon; Joshua Abella; Leon Hsu; Paul Chase; Marco Guazzi; Mary Ann Peberdy Journal: Am Heart J Date: 2008-09-16 Impact factor: 4.749
Authors: JoAnn Lindenfeld; Arthur M Feldman; Leslie Saxon; John Boehmer; Peter Carson; Jalal K Ghali; Inder Anand; Steve Singh; Jonathan S Steinberg; Brian Jaski; Teresa DeMarco; David Mann; Patrick Yong; Elizabeth Galle; Fred Ecklund; Michael Bristow Journal: Circulation Date: 2006-12-26 Impact factor: 29.690
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: David J Whellan; Christopher M O'Connor; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston-Miller; Jerome L Fleg; Kevin A Schulman; Ileana L Piña Journal: Am Heart J Date: 2007-02 Impact factor: 4.749
Authors: Jacob P Kelly; Robert J Mentz; Alexandre Mebazaa; Adriaan A Voors; Javed Butler; Lothar Roessig; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor; Carolyn S P Lam Journal: J Am Coll Cardiol Date: 2015-04-28 Impact factor: 24.094
Authors: Richard Severin; Ahmad Sabbahi; Cemal Ozemek; Shane Phillips; Ross Arena Journal: Expert Rev Med Devices Date: 2019-09-06 Impact factor: 3.166
Authors: Yasmin Hamirani; Ibrahim Fanous; Christopher M Kramer; Andrew Wong; Michael Salerno; Patrick Dillon Journal: Med Oncol Date: 2016-06-22 Impact factor: 3.064
Authors: Apolline Adé; Frédérique Debroucker; Laura Delporte; Cécile De Monclin; Emmanuel Fayet; Pierre Legendre; Lise Radoszycki; Michael Chekroun Journal: BMC Health Serv Res Date: 2020-06-05 Impact factor: 2.655
Authors: Anneleen Baert; Sofie Pardaens; Delphine De Smedt; Paolo Emilio Puddu; Maria Costanza Ciancarelli; Amos Dawodu; Johan De Sutter; Dirk De Bacquer; Els Clays Journal: Int J Environ Res Public Health Date: 2019-05-05 Impact factor: 3.390
Authors: Sandra M Miranda; Samuel D Moscavitch; Larissa R Carestiato; Renata M Felix; Ronaldo C Rodrigues; Leandro R Messias; Jader C Azevedo; Antonio Cláudio L Nóbrega; Evandro Tinoco Mesquita; Claudio Tinoco Mesquita Journal: Arq Bras Cardiol Date: 2013-07 Impact factor: 2.000
Authors: R M Cubbon; A Woolston; B Adams; C P Gale; M S Gilthorpe; P D Baxter; L C Kearney; B Mercer; A Rajwani; P D Batin; M Kahn; R J Sapsford; K K Witte; M T Kearney Journal: Heart Date: 2014-03-19 Impact factor: 5.994